[Polycythemia vera: current status of therapy].
Lengfelder
E
E
III. Medizinische Universitätsklinik Mannheim.
Hehlmann
R
R
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001815:Bloodletting; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D007938:Leukemia / Q000209:etiology; D008875:Middle Aged; D018962:Phlebotomy; D010885:Pipobroman / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011087:Polycythemia Vera / Q000150:complications / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D011446:Prospective Studies; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D013923:Thromboembolism / Q000517:prevention & control
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D005343:Fibrinolytic Agents; D016898:Interferon-alpha; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; D010885:Pipobroman; C021139:anagrelide; D006918:Hydroxyurea